Cocrystal Pharma to Present at the H.C. Wainwright Global Life Sciences Virtual Conference
Cocrystal Pharma (Nasdaq: COCP) announced its participation in the H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Cocrystal Pharma (Nasdaq: COCP) announced its participation in the H.C. Wainwright Global Life Sciences Virtual Conference on January 9-10, 2021, where management will present a company overview and engage in virtual investor meetings. Interested participants can access the presentation by registering for the conference. The webcast will be available from March 9, 2021, at 7:00 a.m. Eastern time to March 10, 2021, at 9:00 p.m. Eastern time. Cocrystal specializes in developing antiviral therapeutics targeting various viruses, including SARS-CoV-2 and influenza.
Details
News Market Reaction – COCP
The recorded move for COCP in the trading session of this news was +1.27%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOTHELL, Wash., March 02, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP), (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, the SARS-CoV-2 virus, hepatitis C viruses and noroviruses, announces that management will present a company overview and hold virtual investor meetings at the H.C. Wainwright Global Life Sciences Virtual Conference being held January 9-10, 2021.
The Cocrystal Pharma webcast presentation can be accessed by registering for the H.C. Wainwright Global Life Sciences Virtual Conference here. The webcast will be available on the H.C. Wainwright Conference Portal beginning March 9, 2021 at 7:00 a.m. Eastern time through March 10, 2021 at 9:00 p.m. Eastern time. The Company’s corporate presentation can be accessed from the Investor Relations section of the Company website here.
About Cocrystal Pharma, Inc.
Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), hepatitis C viruses and noroviruses. Cocrystal employs unique structure-based technologies and Nobel Prize-winning expertise to create first- and best-in-class antiviral drugs. For further information about Cocrystal, please visit www.cocrystalpharma.com.
Investor Contact:
LHA Investor Relations
Jody Cain
310-691-7100
jcain@lhai.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.